 |
|
0 new discussion posts (1 published)
Sign in to view your progression
|
PARP Ihibitors are now a part of standard management of patients with high grade serous carcinoma. This relatively new agents are used in maintenance therapy in patients with or without BRCA mutations.
The e-module covers the essential information about the indications for PARP inhibitors in first line and recurrent disease and gives an insight of possible future combination of these drugs. The second section focuses on HRD and genetic testing, that is essential for an adequate therapeutic choice of a PARP inhibitor.
At the end of the e-module, there is an MCQ test, in order to evaluate and improve your knowledge. The number of the test attempts is unlimited.
You can watch the lectures in any order that you like but you will only have access to the module post-test after viewing all the lectures within the module.
After you have successfully completed the post-test and the evaluation, you will be able to submit your feedback to the course and download your certificate.
- To learn about the indications of PARP inhibitors in frontline and recurrent setting
- To acquire knowledge about HRD and genetic testing
- To understand How HRD and genetic testing might be applied to using PARP inhibitors
- To obtain knowledge about future perspectives combinations of PARP - inhibitors
|
ACCREDITED ACTIVITY
Session 1: PARP inhibitors | PARP in recurrent disease
|
|
|
ACCREDITED ACTIVITY
Session 1: PARP inhibitors | First line
|
|
|
ACCREDITED ACTIVITY
Session 1: PARP inhibitors | Future combinations
|
|
|
ACCREDITED ACTIVITY
Session 2: HRD Testing | HRD and genetic testing
|
|
|
ACCREDITED ACTIVITY
Session 2: HRD Testing | How HRD and genetic testing might be applied to using PARP inhibitors
|
|
|
ACCREDITED ACTIVITY
Session 2: HRD Testing | Other ways of looking at phenomenon of HRD - perhaps the European (ENGOT) initiative on HRD assays?
|
|
|
ASSESSMENT & CERTIFICATE
Assessment and Certificate
|
|
